Type of non Hodgkin's lymphoma-Other-Marginal zone B-cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Other-Marginal zone B-cell lymphoma Posts on Medivizor

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...

Read More

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Posted by on Dec 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of bendamustine (Treanda), ofatumumab (Arzerra), carboplatin (Paraplatin), and etoposide (Etopophos) in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).   This study concluded that this combination was safe and effective in these...

Read More

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Posted by on Oct 4, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of 177Lu-lilotomab satetraxetan (177LLS; Betalutin) in patients with relapsed/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL). The main finding was that 177LLS was proven to be a valuable alternative treatment in such patients. Some background NHL is a type of lymphoma that spreads...

Read More

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Posted by on Sep 13, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the effectiveness and safety of lisocabtagene maraleucel (Liso-cel) in treating patients with relapsed or refractory (r/r) large B-cell lymphomas (LBCL). The authors found that liso-cel achieved fast and lasting remission with fewer toxicities in such patients. Some background Patients with r/r-LBCL experience...

Read More

Treating patients with B-cell non-Hodgkin lymphoma with immunoglobulin replacement therapy after rituximab treatment

Treating patients with B-cell non-Hodgkin lymphoma with immunoglobulin replacement therapy after rituximab treatment

Posted by on Sep 6, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the outcomes of immunoglobulin replacement (IgR) therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL) and immunodeficiency, who were previously treated with rituximab (Rituxan). The authors found that IgR was safe and effective to increase serum immunoglobulins in such patients. Some background B-NHL happens...

Read More

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Posted by on Jul 28, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at axicabtagene ciloleucel (Yescarta) to treat B-cell non-Hodgkin lymphoma which has returned after previous treatment outside of clinical trials. It found that most patients responded to this immune therapy and that some patients had a complete response. Some background B-cell non-Hodgkin lymphomas (NHL) are a group of...

Read More

Which chemotherapy combination causes less kidney damage to patients with non-Hodgkin lymphoma?

Posted by on May 9, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP. Some background Combinations of chemotherapy...

Read More

Evaluating biosimilar rituximab for patients with non-Hodgkin’s lymphoma

Posted by on Dec 7, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of BCD-020 (biosimilar rituximab) to rituximab (Rituxan) in patients with non-Hodgkin’s lymphoma (NHL). This study found that BCD-020 was just as effective as standard rituximab, with manageable side effects. Some background Rituximab is commonly used in the treatment of NHL....

Read More

Comparing chemotherapy dosing approaches for patients with non-Hodgkin lymphoma before a stem cell transplant

Posted by on Nov 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated two different dosing approaches for busulfan (Busilvex) chemotherapy for patients with non-Hodgkin lymphoma (NHL) before an autologous stem cell transplant (SCT). The authors found that personalizing treatment dose for these patients was more effective than conventional weight-based dosing. Some background...

Read More